title: The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state.
abstract: We investigated whether culture conditions could affect the RANTES antiviral effect on human immunodeficiency virus type 1 (HIV-1) infection of primary macrophages. Monocyte-derived macrophages (MDM) were obtained either as (1) the adherent cells of 5-day cultures of blood mononuclear cells (PBMC), followed by 2 days without nonadherent PBMC or added cytokines (MDM-5d), or (2) as the adherent cells recovered from 1-h incubation of PBMC, which were cultured for 7 days with macrophage colony-stimulating factor (M-CSF; MDM-MCSF). Infection of MDM-5d from different donors with HIV-1 R5 strains was reproducibly inhibited by RANTES (IC50 < or = 10 nM), but infection of MDM-MCSF was not inhibited by > or = 100 nM RANTES, even when added at initiation of cultures, although it was still inhibited by a CD4 antibody. RANTES had no antiviral effect when MDM-5d were treated with physiological concentrations of M-CSF or GM-CSF before infection. CCR5 and CXCR4 expression as well as that of other cell surface molecules, including adhesion molecules, was not affected by the cytokines. MDM-MCSF from delta 32CCR5 homozygous individuals did not render them permissive to HIV-1, suggesting that it is unlikely that the virus uses another coreceptor. RANTES binding to MDM was chondroitin sulfate, but not heparan sulfate, dependent, and RANTES bound more efficiently to MDM-5d than to MDM-MCSF. Chondroitin sulfate removal partially offset the RANTES antiviral effect for MDM-5d. Thus RANTES anti-HIV-1 activity for primary macrophages depends on culture conditions and their consequent activation status, which may lead to differences in proteoglycan surface expression. These data may be relevant for the development of chemokine-based therapy for HIV-1 infection.
authors.affiliation: Laboratoire de Biochimie, Faculté des Sciences, Rabat, Morocco.
authors.forename: S
authors.initials: S
authors.lastname: Amzazi
authors.forename: L
authors.initials: L
authors.lastname: Ylisastigui
authors.forename: Y
authors.initials: Y
authors.lastname: Bakri
authors.forename: L
authors.initials: L
authors.lastname: Rabehi
authors.forename: L
authors.initials: L
authors.lastname: Gattegno
authors.forename: M
authors.initials: M
authors.lastname: Parmentier
authors.forename: J C
authors.initials: JC
authors.lastname: Gluckman
authors.forename: A
authors.initials: A
authors.lastname: Benjouad
mesh_terms: D002448:Cell Adhesion; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000494:pharmacology*; D002809:Chondroitin Sulfates / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D015658:HIV Infections / Q000378:metabolism*; D015497:HIV-1 / Q000187:drug effects / Q000472:pathogenicity*; D006497:Heparan Sulfate / Q000378:metabolism; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000821:virology; D008262:Macrophage Activation / Q000187:drug effects; D016173:Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000821:virology*
chemical_list: D018946:Chemokine CCL5; D002809:Chondroitin Sulfates; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006497:Heparan Sulfate; D016173:Macrophage Colony-Stimulating Factor